BD (Becton, Dickinson and Company), a leading global medical technology company, announced it has received US Food and Drug Administration (FDA) approval for its BD Totalys MultiProcessor and BD Totalys SlidePrep instruments.

Together with the BD FocalPoint SlideProfiler, these innovations comprise the full BD Totalys System, which further automates slide preparation, imaging and review for use in cervical cancer screening, as well as providing ancillary testing aliquot capability. Increasing automation in the laboratory helps to reduce the potential for human error and increases lab workflow efficiency. The BD DataLink middleware connects the BD Totalys instruments to a Laboratory Information System, improving laboratory efficiency while providing continuous sample tracking to ensure patients get the right results.

The BD Totalys System combined with the BD SurePath liquid-based Pap test offers an improved automated process for cervical cancer screening laboratories versus current methods.

“We are very pleased to introduce the BD Totalys System in the United States,” said Doug White, vice president and general manager, Women’s Health & Molecular Diagnostics. “The BD Totalys System provides clinical laboratories with a highly customizable, automated liquid-based cytology solution to help improve laboratory efficiency, enhance sample tracking and maintain high quality diagnostic results.”

The BD Totalys System provides a balance of automation and flexibility to help meet the needs of medium and high throughput cervical cancer screening labs by increasing workflow efficiency, reducing technician hands-on time and repetitive motion and improving usability, user safety, overall process quality and functionality.